Increased soluble urokinase plasminogen activator receptor (suPAR) levels in neovascular age-related macular degeneration: a role for inflammation in the pathogenesis of the disease?
- 21 Downloads
To evaluate the plasma concentration of the soluble form of the urokinase-type plasminogen activator receptor ((s)uPAR), an established biomarker of chronic inflammation, in patients affected by neovascular age-related macular degeneration.
Forty consecutive patients affected by age-related macular degeneration and 52 subjects with no history of the disease were included in this case–control study. The two groups of individuals considered for the study were matched for age, sex, and class of medications taken. Plasma concentration of suPAR was measured using a specific ELISA assay (suPARnostic, Birkeroed, Denmark).
The case and control groups were similar for age, gender distribution, weight, height, and systolic and diastolic blood pressure, as well as for dyslipidemia and high blood pressure medication (P > 0.28). The plasma concentrations of suPAR were significantly increased in patients with neovascular age-related macular degeneration when compared to controls (6.19 ± 2.2 ng/ml, vs 5.21 ± 1.5, respectively, mean ± SD P = 0.01).
Patients with neovascular age-related macular degeneration display increased plasma levels of suPAR, suggesting that chronic inflammation may be involved in the pathogenesis of the disease.
KeywordsNeovascular age-related macular degeneration Soluble urokinase plasminogen activator receptor Inflammation Prevention
This study was supported by a Grant from the International Agency for the Prevention of Blindness (IAPB), Italian section (Dr Scotti).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 5.Del Rosso M, Fibbi G, Matucci Cerinic M (1999) The urokinase-type plasminogen activator system and inflammatory joint diseases. Clin Exp Rheumatol 17(4):485–498Google Scholar
- 6.Toldi G, Bekő G, Kádár G, Mácsai E, Kovács L, Vásárhelyi B, Balog A (2013) Soluble urokinase soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission. Clin Chem Lab Med 51(2):327–332. https://doi.org/10.1515/cclm-2012-0221 CrossRefGoogle Scholar
- 9.Alexander JP, Bradley JMB, Gabourel JD, Acott TS (1990) Expression of matrix metalloproteinases and inhibitor by human retinal pigment epithelium. Invest Ophthalmol Vis Sci 31(12):2520–2528Google Scholar
- 10.Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Monés J, Richard G, Bandello F, European Society of Retina Specialists (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98(9):1144–1167. https://doi.org/10.1136/bjophthalmol-2014-305702 CrossRefGoogle Scholar
- 12.Cascella R, Strafella C, Longo G, Ragazzo M, Manzo L, De Felici C, Errichiello V, Caputo V, Viola F, Eandi CM, Staurenghi G, Cusumano A, Mauriello S, Marsella LT, Ciccacci C, Borgiani P, Sangiuolo F, Novelli G, Ricci F, Giardina E (2017) Uncovering genetic and non-genetic biomarkers specific for exudative age-related macular degeneration: significant association of twelve variants. Oncotarget 9(8):7812–7821. https://doi.org/10.18632/oncotarget.23241 Google Scholar
- 16.Iannaccone A, Neeli I, Krishnamurthy P, Lenchik NI, Wan H, Gerling IC, Desiderio DM, Radic MZ (2012) Autoimmune biomarkers in age-related macular degeneration: a possible role player in diseasedevelopment and progression. Adv Exp Med Biol 723:11–16. https://doi.org/10.1007/978-1-4614-0631-0_2 CrossRefGoogle Scholar
- 17.Paun CC, Ersoy L, Schick T, Groenewoud JM, Lechanteur YT, Fauser S, Hoyng CB, de Jong EK, denHollander AI (2015) Genetic variants and systemic complement activation levels are associated with serum lipoprotein levels in age-related macular degeneration. Invest Ophthalmol Vis Sci 56(13):7766–7773. https://doi.org/10.1167/iovs.15-17035 CrossRefGoogle Scholar
- 20.Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Høyer-Hansen G, Rønne E, Dybkjaer E, Danø K, Brünner N (1997) ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43(10):1868–1876Google Scholar
- 25.Liu B, Wei L, Meyerle C, Tuo J, Sen HN, Li Z, Chakrabarty S, Agron E, Chan CC, Klein ML, Chew E, Ferris F, Nussenblatt RB (2011) Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration. J Transl Med 9:1–12. https://doi.org/10.1186/1479-5876-9-111 CrossRefGoogle Scholar
- 28.Ding X, Patel M, Chan CC (2009) Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 28(1):1–18. https://doi.org/10.1016/j.preteyeres.2008.10.001
- 29.Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268(3):296–308. https://doi.org/10.1111/j.1365-2796.2010.02252.x CrossRefGoogle Scholar
- 32.Avan A, Tavakoly Sany SB, Ghayour-Mobarhan M, Rahimi HR, Tajfard M, Ferns G (2018) Serum C-reactive protein in the prediction of cardiovascular diseases: overview of the latest clinical studies and public health practice. J Cell Physiol. https://doi.org/10.1002/jcp.26791
- 34.Ichihara N, Miyamura M, Maeda D, Fujisaka T, Fujita SI, Morita H, Takeda Y, Ito T, Sohmiya K, Hoshiga M, Ishizaka N (2017) Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation. J Arrhythm 33(5):469–474. https://doi.org/10.1016/j.joa.2017.05.003 CrossRefGoogle Scholar